First human test of new cancer drug begins
NCT ID NCT04446351
Summary
This is the first study in people to test a new cancer drug called GSK6097608. It aims to find a safe dose and see how the body handles the drug when given alone or combined with other cancer treatments. The study includes about 107 adults with advanced solid tumors that have not responded to standard therapies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Los Angeles, California, 90025, United States
-
GSK Investigational Site
Boston, Massachusetts, 02215, United States
-
GSK Investigational Site
Dallas, Texas, 75230, United States
-
GSK Investigational Site
Houston, Texas, 77030-4009, United States
-
GSK Investigational Site
San Antonio, Texas, 78229, United States
-
GSK Investigational Site
Ottawa, Ontario, K1H 8L6, Canada
-
GSK Investigational Site
Toronto, Ontario, M5G 1Z5, Canada
-
GSK Investigational Site
Chiba, 277-8577, Japan
-
GSK Investigational Site
Tokyo, 104-0045, Japan
-
GSK Investigational Site
Seoul, 03080, South Korea
-
GSK Investigational Site
Seoul, 06351, South Korea
Conditions
Explore the condition pages connected to this study.